The main drawback of the design based on the graph model is related to the generation of the vectors that constitute the graph representation. Mercado et al have established a model for molecular design based on graphs using neural networks and the canonical SMILES as the unit of departure. This robust work provides a perspective with immense potential for de novo design that can significantly impact drug discovery and development programs in pharmaceutical companies .